1
|
Fallani A, Medrano Sandonas L, Tkatchenko A. Inverse mapping of quantum properties to structures for chemical space of small organic molecules. Nat Commun 2024; 15:6061. [PMID: 39025883 PMCID: PMC11258234 DOI: 10.1038/s41467-024-50401-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 07/01/2024] [Indexed: 07/20/2024] Open
Abstract
Computer-driven molecular design combines the principles of chemistry, physics, and artificial intelligence to identify chemical compounds with tailored properties. While quantum-mechanical (QM) methods, coupled with machine learning, already offer a direct mapping from 3D molecular structures to their properties, effective methodologies for the inverse mapping in chemical space remain elusive. We address this challenge by demonstrating the possibility of parametrizing a chemical space with a finite set of QM properties. Our proof-of-concept implementation achieves an approximate property-to-structure mapping, the QIM model (which stands for "Quantum Inverse Mapping"), by forcing a variational auto-encoder with a property encoder to obtain a common internal representation for both structures and properties. After validating this mapping for small drug-like molecules, we illustrate its capabilities with an explainability study as well as by the generation of de novo molecular structures with targeted properties and transition pathways between conformational isomers. Our findings thus provide a proof-of-principle demonstration aiming to enable the inverse property-to-structure design in diverse chemical spaces.
Collapse
Affiliation(s)
- Alessio Fallani
- Department of Physics and Materials Science, University of Luxembourg, L-1511, Luxembourg City, Luxembourg.
| | - Leonardo Medrano Sandonas
- Department of Physics and Materials Science, University of Luxembourg, L-1511, Luxembourg City, Luxembourg.
- Institute for Materials Science and Max Bergmann Center of Biomaterials, TU Dresden, 01062, Dresden, Germany.
| | - Alexandre Tkatchenko
- Department of Physics and Materials Science, University of Luxembourg, L-1511, Luxembourg City, Luxembourg.
| |
Collapse
|
2
|
Taylor AM, Bailey C, Belmont LD, Campbell R, Cantone N, Côté A, Crawford TD, Cummings R, DeMent K, Duplessis M, Flynn M, Good AC, Huang HR, Joshi S, Leblanc Y, Murray J, Nasveschuk CG, Neiss A, Poy F, Romero FA, Sandy P, Tang Y, Tsui V, Zawadzke L, Sims RJ, Audia JE, Bellon SF, Magnuson SR, Albrecht BK, Cochran AG. GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1. J Med Chem 2022; 65:11177-11186. [PMID: 35930799 DOI: 10.1021/acs.jmedchem.2c00662] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Bromodomains are acetyllysine recognition domains present in a variety of human proteins. Bromodomains also bind small molecules that compete with acetyllysine, and therefore bromodomains have been targets for drug discovery efforts. Highly potent and selective ligands with good cellular permeability have been proposed as chemical probes for use in exploring the functions of many of the bromodomain proteins. We report here the discovery of a class of such inhibitors targeting the family VIII bromodomains of SMARCA2 (BRM) and SMARCA4 (BRG1), and PBRM1 (polybromo-1) bromodomain 5. We propose one example from this series, GNE-064, as a chemical probe for the bromodomains SMARCA2, SMARCA4, and PBRM1(5) with the potential for in vivo use.
Collapse
Affiliation(s)
- Alexander M Taylor
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Chris Bailey
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Lisa D Belmont
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Robert Campbell
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Nico Cantone
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Alexandre Côté
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Terry D Crawford
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Richard Cummings
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Kevin DeMent
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Martin Duplessis
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Megan Flynn
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Andrew C Good
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Hon-Ren Huang
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Shivangi Joshi
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Yves Leblanc
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Jeremy Murray
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Christopher G Nasveschuk
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Adrianne Neiss
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Florence Poy
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - F Anthony Romero
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Peter Sandy
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Yong Tang
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Vickie Tsui
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Laura Zawadzke
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Robert J Sims
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - James E Audia
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Steven F Bellon
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Steven R Magnuson
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Brian K Albrecht
- Constellation, a Morphosys Company, 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Andrea G Cochran
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
3
|
Brehm M, Heissler S, Afonin S, Levkin PA. Nanomolar Synthesis in Droplet Microarrays with UV-Triggered On-Chip Cell Screening. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2020; 16:e1905971. [PMID: 31985878 DOI: 10.1002/smll.201905971] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Revised: 12/04/2019] [Indexed: 06/10/2023]
Abstract
Miniaturization and parallelization of combinatorial organic synthesis is important to accelerate the process of drug discovery while reducing the consumption of reagents and solvents. This work presents a miniaturized platform for on-chip solid-phase combinatorial library synthesis with UV-triggered on-chip cell screening. The platform is based on a nanoporous polymer coating on a glass slide, which is modified via photolithography to yield arrays of hydrophilic (HL) spots surrounded by superhydrophobic (SH) surface. The combination of HL spots and SH background enables confinement of nanoliter droplets, functioning as miniaturized reactors for the solid-phase synthesis. The polymer serves as support for nanomolar solid-phase synthesis, while a photocleavable linker enables the release of the synthesized compounds into the droplets containing live cells. A 588 compound library of bisamides is synthesized via a four-component Ugi reaction on the chip and products are detected via stamping of the droplet array onto a conductive substrate and subsequent matrix-assisted laser desorption ionization mass spectrometry. The light-induced cleavage shows high flexibility in screening conditions by spatial, temporal, and quantitative control.
Collapse
Affiliation(s)
- Marius Brehm
- Karlsruhe Institute of Technology (KIT), Institute of Toxicology and Genetics, Hermann-von Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
| | - Stefan Heissler
- Karlsruhe Institute of Technology (KIT), Institute of Functional Interfaces, Hermann-von Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
| | - Sergii Afonin
- Karlsruhe Institute of Technology (KIT), Institute of Biological Interfaces (IBG-2), POB 3640, 76021, Karlsruhe, Germany
| | - Pavel A Levkin
- Karlsruhe Institute of Technology (KIT), Institute of Toxicology and Genetics, Hermann-von Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany
- Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry, Fritz-Haber-Weg 6, 76131, Karlsruhe, Germany
| |
Collapse
|
4
|
Thorpe JH, Wall ID, Sinnamon RH, Taylor AN, Stavenger RA. Cocktailed fragment screening by X-ray crystallography of the antibacterial target undecaprenyl pyrophosphate synthase from Acinetobacter baumannii. Acta Crystallogr F Struct Biol Commun 2020; 76:40-46. [PMID: 31929185 PMCID: PMC6957112 DOI: 10.1107/s2053230x19017199] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 12/24/2019] [Indexed: 11/10/2022] Open
Abstract
Direct soaking of protein crystals with small-molecule fragments grouped into complementary clusters is a useful technique when assessing the potential of a new crystal system to support structure-guided drug discovery. It provides a robustness check prior to any extensive crystal screening, a double check for assay binding cutoffs and structural data for binding pockets that may or may not be picked out in assay measurements. The structural output from this technique for three novel fragment molecules identified to bind to the antibacterial target Acinetobacter baumannii undecaprenyl pyrophosphate synthase are reported, and the different physicochemical requirements of a successful antibiotic are compared with traditional medicines.
Collapse
Affiliation(s)
- James H. Thorpe
- GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, England
| | - Ian D. Wall
- GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, England
| | - Robert H. Sinnamon
- GlaxoSmithKline, Upper Providence, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA
| | - Amy N. Taylor
- GlaxoSmithKline, Upper Providence, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA
| | - Robert A. Stavenger
- GlaxoSmithKline, Upper Providence, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA
| |
Collapse
|
5
|
Meyer HJ, Turincio R, Ng S, Li J, Wilson B, Chan P, Zak M, Reilly D, Beresini MH, Wong AW. High throughput screening identifies novel, cell cycle-arresting small molecule enhancers of transient protein expression. Biotechnol Prog 2017. [DOI: 10.1002/btpr.2517] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Hermann-Josef Meyer
- Dept. of Early Stage Cell Culture; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Rebecca Turincio
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Shirley Ng
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Juan Li
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Blair Wilson
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Pamela Chan
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Mark Zak
- Dept. of; Discovery Chemistry, Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Dorothea Reilly
- Dept. of Early Stage Cell Culture; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Maureen H. Beresini
- Dept. of Biochemical & Cellular Pharmacology; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| | - Athena W. Wong
- Dept. of Early Stage Cell Culture; Genentech Inc; 1 DNA Way, South San Francisco CA 94080
| |
Collapse
|
6
|
Lee ML, Aliagas I, Feng JA, Gabriel T, O’Donnell TJ, Sellers BD, Wiswedel B, Gobbi A. chemalot and chemalot_knime: Command line programs as workflow tools for drug discovery. J Cheminform 2017; 9:38. [PMID: 29086196 PMCID: PMC5468363 DOI: 10.1186/s13321-017-0228-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Accepted: 06/01/2017] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Analyzing files containing chemical information is at the core of cheminformatics. Each analysis may require a unique workflow. This paper describes the chemalot and chemalot_knime open source packages. Chemalot is a set of command line programs with a wide range of functionalities for cheminformatics. The chemalot_knime package allows command line programs that read and write SD files from stdin and to stdout to be wrapped into KNIME nodes. The combination of chemalot and chemalot_knime not only facilitates the compilation and maintenance of sequences of command line programs but also allows KNIME workflows to take advantage of the compute power of a LINUX cluster. RESULTS Use of the command line programs is demonstrated in three different workflow examples: (1) A workflow to create a data file with project-relevant data for structure-activity or property analysis and other type of investigations, (2) The creation of a quantitative structure-property-relationship model using the command line programs via KNIME nodes, and (3) The analysis of strain energy in small molecule ligand conformations from the Protein Data Bank database. CONCLUSIONS The chemalot and chemalot_knime packages provide lightweight and powerful tools for many tasks in cheminformatics. They are easily integrated with other open source and commercial command line tools and can be combined to build new and even more powerful tools. The chemalot_knime package facilitates the generation and maintenance of user-defined command line workflows, taking advantage of the graphical design capabilities in KNIME. Graphical abstract Example KNIME workflow with chemalot nodes and the corresponding command line pipe.
Collapse
Affiliation(s)
- Man-Ling Lee
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Ignacio Aliagas
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Jianwen A. Feng
- Denali Therapeutics, 151 Oyster Point Blvd, South San Francisco, CA 94080 USA
| | - Thomas Gabriel
- KNIME.com AG, Technoparkstrasse 1, 8005 Zurich, Switzerland
| | | | - Benjamin D. Sellers
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| | - Bernd Wiswedel
- KNIME.com AG, Technoparkstrasse 1, 8005 Zurich, Switzerland
| | - Alberto Gobbi
- Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 USA
| |
Collapse
|
7
|
Pertusi DA, O’Donnell G, Homsher MF, Solly K, Patel A, Stahler SL, Riley D, Finley MF, Finger EN, Adam GC, Meng J, Bell DJ, Zuck PD, Hudak EM, Weber MJ, Nothstein JE, Locco L, Quinn C, Amoss A, Squadroni B, Hartnett M, Heo MR, White T, May SA, Boots E, Roberts K, Cocchiarella P, Wolicki A, Kreamer A, Kutchukian PS, Wassermann AM, Uebele VN, Glick M, Rusinko A, Culberson JC. Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score. SLAS DISCOVERY 2017; 22:995-1006. [DOI: 10.1177/2472555217706058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
High-throughput screening (HTS) is a widespread method in early drug discovery for identifying promising chemical matter that modulates a target or phenotype of interest. Because HTS campaigns involve screening millions of compounds, it is often desirable to initiate screening with a subset of the full collection. Subsequently, virtual screening methods prioritize likely active compounds in the remaining collection in an iterative process. With this approach, orthogonal virtual screening methods are often applied, necessitating the prioritization of hits from different approaches. Here, we introduce a novel method of fusing these prioritizations and benchmark it prospectively on 17 screening campaigns using virtual screening methods in three descriptor spaces. We found that the fusion approach retrieves 15% to 65% more active chemical series than any single machine-learning method and that appropriately weighting contributions of similarity and machine-learning scoring techniques can increase enrichment by 1% to 19%. We also use fusion scoring to evaluate the tradeoff between screening more chemical matter initially in lieu of replicate samples to prevent false-positives and find that the former option leads to the retrieval of more active chemical series. These results represent guidelines that can increase the rate of identification of promising active compounds in future iterative screens.
Collapse
Affiliation(s)
- Dante A. Pertusi
- Modeling and Informatics, Merck & Co., Inc., West Point, PA, USA
| | - Gregory O’Donnell
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Michelle F. Homsher
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Kelli Solly
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Amita Patel
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Shannon L. Stahler
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Daniel Riley
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Michael F. Finley
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA
| | - Eleftheria N. Finger
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Discovery & Preclinical Development, GlaxoSmithKline, Collegeville, PA, USA
| | - Gregory C. Adam
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., West Point, PA, USA
| | - Juncai Meng
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
| | - David J. Bell
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., North Wales, PA, USA
| | - Paul D. Zuck
- Merck & Co., Inc., North Wales, PA, USA
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Edward M. Hudak
- Discovery Sample Management, Merck & Co., Inc., North Wales, PA, USA
| | - Michael J. Weber
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Jennifer E. Nothstein
- Merck & Co., Inc., West Point, PA, USA
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Louis Locco
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Carissa Quinn
- Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Adam Amoss
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Brian Squadroni
- Merck & Co., Inc., West Point, PA, USA
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Michelle Hartnett
- Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Mee Ra Heo
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., North Wales, PA, USA
| | - Tara White
- Discovery Sample Management, Merck & Co., Inc., North Wales, PA, USA
| | - S. Alex May
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | - Evelyn Boots
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
| | - Kenneth Roberts
- Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA
| | | | - Alex Wolicki
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
| | - Anthony Kreamer
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | | | - Victor N. Uebele
- Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA
- Merck & Co., Inc., North Wales, PA, USA
| | - Meir Glick
- Modeling and Informatics, Merck & Co., Inc., Boston, MA, USA
| | - Andrew Rusinko
- Modeling and Informatics, Merck & Co., Inc., West Point, PA, USA
| | | |
Collapse
|
8
|
Tsui V, Ortwine DF, Blaney JM. Enabling drug discovery project decisions with integrated computational chemistry and informatics. J Comput Aided Mol Des 2016; 31:287-291. [DOI: 10.1007/s10822-016-9988-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 10/22/2016] [Indexed: 01/24/2023]
|
9
|
Crawford TD, Romero FA, Lai KW, Tsui V, Taylor AM, de Leon Boenig G, Noland CL, Murray J, Ly J, Choo EF, Hunsaker TL, Chan EW, Merchant M, Kharbanda S, Gascoigne KE, Kaufman S, Beresini MH, Liao J, Liu W, Chen KX, Chen Z, Conery AR, Côté A, Jayaram H, Jiang Y, Kiefer JR, Kleinheinz T, Li Y, Maher J, Pardo E, Poy F, Spillane KL, Wang F, Wang J, Wei X, Xu Z, Xu Z, Yen I, Zawadzke L, Zhu X, Bellon S, Cummings R, Cochran AG, Albrecht BK, Magnuson S. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. J Med Chem 2016; 59:10549-10563. [PMID: 27682507 DOI: 10.1021/acs.jmedchem.6b01022] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The single bromodomain of the closely related transcriptional regulators CBP/EP300 is a target of much recent interest in cancer and immune system regulation. A co-crystal structure of a ligand-efficient screening hit and the CBP bromodomain guided initial design targeting the LPF shelf, ZA loop, and acetylated lysine binding regions. Structure-activity relationship studies allowed us to identify a more potent analogue. Optimization of permeability and microsomal stability and subsequent improvement of mouse hepatocyte stability afforded 59 (GNE-272, TR-FRET IC50 = 0.02 μM, BRET IC50 = 0.41 μM, BRD4(1) IC50 = 13 μM) that retained the best balance of cell potency, selectivity, and in vivo PK. Compound 59 showed a marked antiproliferative effect in hematologic cancer cell lines and modulates MYC expression in vivo that corresponds with antitumor activity in an AML tumor model.
Collapse
Affiliation(s)
- Terry D Crawford
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - F Anthony Romero
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Kwong Wah Lai
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Vickie Tsui
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Alexander M Taylor
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | | | - Cameron L Noland
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Jeremy Murray
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Justin Ly
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Edna F Choo
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Thomas L Hunsaker
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Emily W Chan
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Mark Merchant
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Samir Kharbanda
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Karen E Gascoigne
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Susan Kaufman
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Maureen H Beresini
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Jiangpeng Liao
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Wenfeng Liu
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Kevin X Chen
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Zhongguo Chen
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Andrew R Conery
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Alexandre Côté
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Hariharan Jayaram
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Ying Jiang
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - James R Kiefer
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Tracy Kleinheinz
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Yingjie Li
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Jonathan Maher
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Eneida Pardo
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Florence Poy
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Kerry L Spillane
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Fei Wang
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Jian Wang
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Xiaocang Wei
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Zhaowu Xu
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Zhongya Xu
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Ivana Yen
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Laura Zawadzke
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Xiaoyu Zhu
- Wuxi Apptec Co., Ltd. , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China
| | - Steven Bellon
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Richard Cummings
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Andrea G Cochran
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Brian K Albrecht
- Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States
| | - Steven Magnuson
- Genentech, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
10
|
Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Mol Divers 2016; 20:789-803. [PMID: 27631533 PMCID: PMC5055576 DOI: 10.1007/s11030-016-9692-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Accepted: 07/29/2016] [Indexed: 01/07/2023]
Abstract
High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer.
Collapse
|
11
|
Wasko MJ, Pellegrene KA, Madura JD, Surratt CK. A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets. Front Neurol 2015; 6:197. [PMID: 26441817 PMCID: PMC4566055 DOI: 10.3389/fneur.2015.00197] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 08/24/2015] [Indexed: 01/12/2023] Open
Abstract
Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. Lead compound development is an area ripe for new design strategies. Therapeutic lead candidates have been traditionally found using high-throughput in vitro pharmacological screening, a costly method for assaying thousands of compounds. This approach has recently been augmented by virtual screening (VS), which employs computer models of the target protein to narrow the search for possible leads. A variant of VS is fragment-based drug design (FBDD), an emerging in silico lead discovery method that introduces low-molecular weight fragments, rather than intact compounds, into the binding pocket of the receptor model. These fragments serve as starting points for “growing” the lead candidate. Current efforts in virtual FBDD within central nervous system (CNS) targets are reviewed, as is a recent rule-based optimization strategy in which new molecules are generated within a 3D receptor-binding pocket using the fragment as a scaffold. This process not only places special emphasis on creating synthesizable molecules but also exposes computational questions worth addressing. Fragment-based methods provide a viable, relatively low-cost alternative for therapeutic lead discovery and optimization that can be applied to CNS targets to augment current design strategies.
Collapse
Affiliation(s)
- Michael J Wasko
- Mylan School of Pharmacy, Graduate School of Pharmaceutical Sciences, Duquesne University , Pittsburgh, PA , USA
| | - Kendy A Pellegrene
- Mylan School of Pharmacy, Graduate School of Pharmaceutical Sciences, Duquesne University , Pittsburgh, PA , USA
| | - Jeffry D Madura
- Department of Chemistry and Biochemistry, Center for Computational Sciences, Bayer School of Natural and Environmental Sciences, Duquesne University , Pittsburgh, PA , USA
| | - Christopher K Surratt
- Mylan School of Pharmacy, Graduate School of Pharmaceutical Sciences, Duquesne University , Pittsburgh, PA , USA
| |
Collapse
|
12
|
Increasing the delivery of next generation therapeutics from high throughput screening libraries. Curr Opin Chem Biol 2015; 26:104-10. [PMID: 25909818 DOI: 10.1016/j.cbpa.2015.04.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 04/02/2015] [Accepted: 04/03/2015] [Indexed: 12/14/2022]
Abstract
The pharmaceutical industry has historically relied on high throughput screening as a cornerstone to identify chemical equity for drug discovery projects. However, with pharmaceutical companies moving through a phase of diminished returns and alternative hit identification strategies proving successful, it is more important than ever to understand how this approach can be used more effectively to increase the delivery of next generation therapeutics from high throughput screening libraries. There is a wide literature that describes HTS and fragment based screening approaches which offer clear direction on the process for these two distinct activities. However, few people have considered how best to identify medium to low molecular weight compounds from large diversity screening sets and increase downstream success.
Collapse
|
13
|
Gobbi A, Giannetti AM, Chen H, Lee ML. Atom-Atom-Path similarity and Sphere Exclusion clustering: tools for prioritizing fragment hits. J Cheminform 2015; 7:11. [PMID: 25866564 PMCID: PMC4392110 DOI: 10.1186/s13321-015-0056-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 02/09/2015] [Indexed: 11/10/2022] Open
Abstract
Background After performing a fragment based screen the resulting hits need to be prioritized for follow-up structure elucidation and chemistry. This paper describes a new similarity metric, Atom-Atom-Path (AAP) similarity that is used in conjunction with the Directed Sphere Exclusion (DISE) clustering method to effectively organize and prioritize the fragment hits. The AAP similarity rewards common substructures and recognizes minimal structure differences. The DISE method is order-dependent and can be used to enrich fragments with properties of interest in the first clusters. Results The merit of the software is demonstrated by its application to the MAP4K4 fragment screening hits using ligand efficiency (LE) as quality measure. The first clusters contain the hits with the highest LE. The clustering results can be easily visualized in a LE-over-clusters scatterplot with points colored by the members’ similarity to the corresponding cluster seed. The scatterplot enables the extraction of preliminary SAR. Conclusions The detailed structure differentiation of the AAP similarity metric is ideal for fragment-sized molecules. The order-dependent nature of the DISE clustering method results in clusters ordered by a property of interest to the teams. The combination of both allows for efficient prioritization of fragment hit for follow-ups. AAP similarity computation and DISE clustering visualization. ![]()
Electronic supplementary material The online version of this article (doi:10.1186/s13321-015-0056-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Alberto Gobbi
- Small Molecule Discovery, Discovery Chemistry, Genentech, 1 DNA Way, 94080 South San Francisco, CA USA
| | - Anthony M Giannetti
- Small Molecule Discovery, Biochemical and Cellular Pharmacology, Genentech, 1 DNA Way, 94080 South San Francisco, CA USA
| | - Huifen Chen
- Small Molecule Discovery, Discovery Chemistry, Genentech, 1 DNA Way, 94080 South San Francisco, CA USA
| | - Man-Ling Lee
- Small Molecule Discovery, Discovery Chemistry, Genentech, 1 DNA Way, 94080 South San Francisco, CA USA
| |
Collapse
|
14
|
Nybond S, Ghemtio L, Nawrot DA, Karp M, Xhaard H, Tammela P. Integrated In Vitro–In Silico Screening Strategy for the Discovery of Antibacterial Compounds. Assay Drug Dev Technol 2015; 13:25-33. [DOI: 10.1089/adt.2014.625] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Affiliation(s)
- Susanna Nybond
- Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Leo Ghemtio
- Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Dorota A. Nawrot
- Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Matti Karp
- Department of Chemistry and Bioengineering, Tampere University of Technology, Tampere, Finland
| | - Henri Xhaard
- Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, Finland
| | - Päivi Tammela
- Centre for Drug Research, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| |
Collapse
|
15
|
Green DVS, Clemons PA. Knowledge from Small-Molecule Screening and Profiling Data. JOURNAL OF BIOMOLECULAR SCREENING 2014; 19:611-613. [PMID: 24842910 DOI: 10.1177/1087057114531209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|